In Vitro Studies with UK-18,892, a New Aminoglycoside Antibiotic

AUTOR(ES)

Jevons, S.

RESUMO

The antibacterial activity of UK-18,892, a new semisynthetic aminoglycoside, was examined against aminoglycoside-susceptible and aminoglycoside-resistant clinical isolates of gram-negative bacilli and Staphylococcus aureus. UK-18,892 had a similar degree of activity to those of amikacin and kanamycin A against aminoglycoside-susceptible bacteria but was less potent than gentamicin against all isolates except Providencia spp. UK-18,892 was highly active against aminoglycoside-resistant bacteria, inhibiting 93% of the 268 isolates examined at 12.5 μg/ml. Amikacin was similarly active, whereas gentamicin inhibited only 14% of these isolates at 12.5 μg/ml.

Documentos Relacionados

• Cochlear toxicity of butikacin (UK-18,892), a new semisynthetic aminoglycoside antibiotic, in guinea pigs.
• UK-18,892: Resistance to Modification by Aminoglycoside-Inactivating Enzymes
• UK-18892, a New Aminoglycoside: An In Vitro Study
• In Vitro Studies of Netilmicin, a New Aminoglycoside Antibiotic
• In Vitro Studies of BB-K8, a New Aminoglycoside Antibiotic